Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023

Rhea-AI Summary

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) will report its financial results for the second quarter ended June 30, 2023, on August 7, 2023, after the financial markets close. The conference call will take place on the same day at 4:30 p.m. ET. The company focuses on developing medicines to target diseases driven by abnormally elevated aldosterone.

RADNOR, Pa., July 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2023, after the financial markets close on Monday, August 7, 2023.

Monday, August 7th @ 4:30 p.m. ET
Domestic:	1-877-704-4453
International:	1-201-389-0920
Conference ID:	13739672
Webcast:	Link

If you would like a call back, please click this link, which will be made active 15 minutes prior to the scheduled start time. A live webcast of the conference call may be found here. A replay of the call will be available on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.

About Mineralys
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn.

Contact:
Investor Relations
investorrelations@mineralystx.com

Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com

FAQ

When will Mineralys Therapeutics report its financial results for the second quarter of 2023?

Mineralys Therapeutics will report its financial results for the second quarter of 2023 on August 7, 2023.

What is the stock symbol of Mineralys Therapeutics?

The stock symbol of Mineralys Therapeutics is NASDAQ: MLYS.

What does Mineralys Therapeutics focus on?

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone.

What time is the conference call scheduled?

The conference call is scheduled for Monday, August 7, 2023, at 4:30 p.m. ET.

Where can I find the webcast of the conference call?

The webcast of the conference call can be found on the Mineralys Therapeutics website.

Will there be a replay of the conference call?

Yes, a replay of the conference call will be available on the 'News & Events' page in the Investor Relations section of the Mineralys Therapeutics website.